181 related articles for article (PubMed ID: 37588187)
1. Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin.
Chen Z; Guo Q; Huang S; Li L; Wu F; Liu Z; Li Z; Chen T; Song G; Xu S; Chen J; Hou Y
Genes Dis; 2024 Jan; 11(1):397-412. PubMed ID: 37588187
[TBL] [Abstract][Full Text] [Related]
2. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Bertacchini J; Guida M; Accordi B; Mediani L; Martelli AM; Barozzi P; Petricoin E; Liotta L; Milani G; Giordan M; Luppi M; Forghieri F; De Pol A; Cocco L; Basso G; Marmiroli S
Leukemia; 2014 Nov; 28(11):2197-205. PubMed ID: 24699302
[TBL] [Abstract][Full Text] [Related]
3. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Fooks K; Galicia-Vazquez G; Gife V; Schcolnik-Cabrera A; Nouhi Z; Poon WWL; Luo V; Rys RN; Aloyz R; Orthwein A; Johnson NA; Hulea L; Mercier FE
J Exp Clin Cancer Res; 2022 Dec; 41(1):340. PubMed ID: 36482393
[TBL] [Abstract][Full Text] [Related]
4. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
5. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
6. GNG7 silencing promotes the proliferation and differentiation of placental cytotrophoblasts in preeclampsia rats through activation of the mTOR signaling pathway.
Lai WS; Ding YL
Int J Mol Med; 2019 May; 43(5):1939-1950. PubMed ID: 30864685
[TBL] [Abstract][Full Text] [Related]
7. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.
Su Y; Li X; Ma J; Zhao J; Liu S; Wang G; Edwards H; Taub JW; Lin H; Ge Y
Biochem Pharmacol; 2018 Feb; 148():13-26. PubMed ID: 29208365
[TBL] [Abstract][Full Text] [Related]
8. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.
Zhou J; Toh SH; Chan ZL; Quah JY; Chooi JY; Tan TZ; Chong PSY; Zeng Q; Chng WJ
J Hematol Oncol; 2018 Mar; 11(1):36. PubMed ID: 29514683
[TBL] [Abstract][Full Text] [Related]
9. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
10. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
11. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
13. WTIP upregulates FOXO3a and induces apoptosis through PUMA in acute myeloid leukemia.
Zhu Y; Tong X; Wang Y; Lu X
Cell Death Dis; 2021 Dec; 13(1):18. PubMed ID: 34930905
[TBL] [Abstract][Full Text] [Related]
14. Expression Changes of SIRT1 and FOXO3a Significantly Correlate with Oxidative Stress Resistance Genes in AML Patients.
Mizani S; Keshavarz A; Vazifeh Shiran N; Bashash D; Allahbakhshian Farsani M
Indian J Hematol Blood Transfus; 2023 Jul; 39(3):392-401. PubMed ID: 37304466
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
16. IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.
Chapuis N; Park S; Leotoing L; Tamburini J; Verdier F; Bardet V; Green AS; Willems L; Agou F; Ifrah N; Dreyfus F; Bismuth G; Baud V; Lacombe C; Mayeux P; Bouscary D
Blood; 2010 Nov; 116(20):4240-50. PubMed ID: 20671123
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway.
Lam CF; Yeung HT; Lam YM; Ng RK
Leuk Res; 2018 May; 68():112-119. PubMed ID: 29609096
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
